Developmental Research Program

药物研究报告（DRP）摘要/摘要 本SPORE规划研究的发展研究计划（DRP）的目标是支持 制定并成功完成创新、高风险/高回报的试点项目， 了解或减少儿童急性淋巴细胞白血病（ALL）中基于种族的结果差异。 该计划将由医生科学家Maria Monica Gramatges博士和医生Philip Lupo博士共同领导。 分子流行病学家Gramatges和Lupo博士在转化研究方面都有很好的记录 研究儿童癌症治疗相关毒性的遗传和分子预测因子。他们的 互补的学科和合作的历史证明了DRP对支持 多学科研究。DRP支持的项目可以是临床或翻译项目，但必须解决种族问题。 ALL治疗相关毒性的差异（急性或迟发性）。申请DRP试点补助金的资格将 扩展到参与此应用程序的机构的任何教员。提案将使用 NIH 9分制，并由DRP委员会共同决定资金的选择。 DRP委员会的成员资格将在所有参与研究中心平均分配，以确保公平性， 奖项分配的透明度，并将包括具有临床和转化研究专业知识的教师 并且在参与赠款同行评审方面有着良好的记录。供资标准将与 在上述重点领域被视为高风险/高影响的强有力的科学价值。 代表参与机构之间合作的提案也将得到优先考虑， 来自初级教师和新研究人员的建议（那些没有独立的联邦资助的人）和那些 认为可能导致未来的独立供资。所有试点赠款将颁发一年， 在第一年结束时，有机会一次性续约一年。除了审查赠款和 选择，DRP委员会将负责监测和监督资助的项目，通过定期 审查进度报告和最终报告。DRP的核心使命是为奖学金获得者提供资金 支持，2）获得核心设施，以及3）在奖励期间的指导。总共75，000美元 预算用于支持第一年的三个试点奖，每个奖25，000美元， 每年资助两个试点奖加两个续期，每次续期20，000美元。 所有试点补助PI将被提供访问指定的核心，没有相关的费用，并将 至少需要使用一个核心。DRP委员会将为每个受资助的项目指定一个咨询委员会 该组织将提供针对每个项目的指导和指导。的一个关键作用 咨询委员会将与DRP委员会一起促进 试点补助金数据是独立资助的工作，有可能包括在未来的P50应用程序。

DEVELOPMENTAL RESEARCH PROGRAM (DRP) SUMMARY/ABSTRACT The objective of the Developmental Research Program (DRP) of this SPORE planning study is to support the development and successful completion of innovative, high-risk/high-reward pilot projects that aim to understand or reduce outcome ethnicity-based disparities in childhood acute lymphoblastic leukemia (ALL). This program will be co-led by Dr. Maria Monica Gramatges, a physician scientist, and Dr. Philip Lupo, a molecular epidemiologist. Drs. Gramatges and Lupo each have strong track records in translational research investigating genetic and molecular predictors of treatment-related toxicities in childhood cancer. Their complementary disciplines and history of collaboration evidence a strong commitment of the DRP to supporting multidisciplinary research. DRP-supported projects may be clinical or translational, but must address ethnic disparities in ALL treatment-related toxicities (acute or late onset). Eligibility to apply for a DRP Pilot Grant will extend to any faculty member of an institution participating in this application. Proposals will be scored using the NIH 9 point system, and selection for funding will be jointly determined by the DRP Committee. Membership to the DRP Committee will be distributed equally across all participating sites to ensure equity and transparency in award distribution, and will include faculty with expertise in clinical and translational research and who have a strong track record of participation in grant peer review. Criteria for funding will be work with strong scientific merit that is perceived as high-risk/high-impact in the above listed areas of concentration. Proposals representing collaborations between participating institutions will also be prioritized, as will proposals from junior faculty and new investigators (those with no prior independent federal funding) and those considered likely to result in future independent funding. All Pilot Grants will be awarded for one year, with an opportunity for a one-time, one-year renewal at the end of the first year. In addition to grant review and selection, the DRP Committee will be responsible for monitoring and oversight of funded projects via regular review of progress and final reports. The DRP's core mission is to provide grant awardees with 1) funding support, 2) access to core facilities, and 3) mentorship during the award period. A total of $75,000 will be budgeted to support funding of three Pilot Awards in Year 1 at $25,000 per award, and $90,000 per year in each subsequent year to support funding two Pilot Awards per year plus two renewals at $20,000 per renewal. All Pilot Grant PI's will be provided with access to the designated Cores with no associated cost, and will be required to use at least one Core. The DRP Committee will assign each funded project an Advisory Committee with relevant expertise, who will provide mentorship and guidance that is specific to each project. A key role of the Advisory Committee, together with the DRP Committee, will be to facilitate the transition/development of Pilot Grant data to work that is independently funded, with potential inclusion in a future P50 application.